The Impact of Smoking on Urologic Outcomes

@inproceedings{Feng2016TheIO,
  title={The Impact of Smoking on Urologic Outcomes},
  author={Tom Feng and Devin N Patel and Dhruv Khullar and Mark Vogel and John Maa},
  year={2016}
}
Purpose: Cigarette smoking is the leading preventable cause of morbidity and mortality in the US and worldwide. The surgical literature demonstrates that active tobacco smoking is a major risk factor for perioperative morbidity and complications, and that preoperative smoking cessation is effective in reducing these associated risks. However, few studies have examined the dual effects of smoking on the etiology and treatment of urologic conditions, and perioperative complications following… Expand

References

SHOWING 1-10 OF 72 REFERENCES
Smoking and Perioperative Outcomes
TLDR
It is indicated that smoking is associated with a higher likelihood of 30-day mortality and serious postoperative complications and a broad range of serious smoking-related complications may enhance the clinician's ability to motivate smoking cessation in surgical patients. Expand
Brief smoking cessation intervention: a prospective trial in the urology setting.
TLDR
The role of the urologist in providing smoking cessation assistance and the significant impact of brief, simple advice about quitting smoking on the smoker quit rate are highlighted. Expand
Ethnicity and smoking status are associated with awareness of smoking related genitourinary diseases.
TLDR
There is a need for increased awareness of smoking related genitourinary diseases, especially among minority patients and smokers, and for urologists to provide smoking cessation assistance and education for this patient population. Expand
Evaluating the effectiveness of a smoking warning label on raising patient awareness of smoking and bladder cancer.
TLDR
Awareness of the link between smoking and bladder cancer remains low and the use of a smoking warning label may help raise awareness of this important public health issue. Expand
The effect of smoking on spontaneous passage of distal ureteral stones
TLDR
Smoking has neither a favorable nor un-favorable effect on spontaneous passage of distal ureteral stones, however, spontaneous passage rates in patients with a stone diameter > 4 mm was lower in smokers. Expand
Smoking cessation assistance for patients with bladder cancer: a national survey of American urologists.
TLDR
Urologists who are trained in smoking cessation most commonly provide smoking cessation assistance and recommend integrating formal smoking cessation instruction into courses that address bladder cancer and strongly encourage the American Urological Association to adopt practice pattern guidelines. Expand
Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy.
TLDR
Smoking is associated with worse prognosis after RC for UCB, and its effects are mitigated by >10 yr smoking cessation; health care practitioners should counsel smokers regarding the detrimental effects of smoking and the benefits of smoking cessation. Expand
Smoking and erectile dysfunction: evidence based analysis.
TLDR
There are strong parallels and shared risks among smoking, coronary artery disease, atherosclerosis and erectile dysfunction, and clinical and basic science studies provide strong indirect evidence that smoking may affect penile erection by the impairment of endothelium dependent smooth muscle relaxation. Expand
Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer.
TLDR
Smoking status and a higher cumulative smoking exposure are associated with worse prognosis in patients with primary non-muscle-invasive bladder cancer and the need for integrated smoking cessation and prevention programmes in the management of NMIBC patients is underscored. Expand
Smoking, The Missing Drug Interaction in Clinical Trials: Ignoring the Obvious
TLDR
It is recommended that smoking history and status be systematically collected as core data in all oncology clinical trials: at diagnosis, at trial registration, and throughout treatment and follow-up to long-term survival or death. Expand
...
1
2
3
4
5
...